Managing Dental Sedation
Documents the ASA sedation continuum for dental patients, including patient selection, pre-sedation assessment, intraoperative monitoring, drug protocols, and discharge criteria for minimal, moderate, and deep sedation.
Why This Skill Exists
Sedation-related adverse events are the leading cause of dental office mortality. Between 2000 and 2020, over 100 documented deaths in US dental offices were attributable to sedation complications — most involving airway compromise in inadequately monitored patients. The ASA sedation continuum means that every patient receiving sedation can unpredictably progress to a deeper level, and the provider must be trained and equipped to rescue from one level deeper than intended.
State dental boards regulate sedation permits with specific staffing, equipment, training, and documentation requirements that vary by sedation level. This skill structures the entire sedation workflow from patient selection through discharge, ensuring compliance with ADA Guidelines for the Use of Sedation and General Anesthesia by Dentists (2016, revised) and state-specific regulations.
Checkpoint A: Pre-Sedation Intake (Mandatory)
- What sedation level is planned (minimal/anxiolysis, moderate, deep, general anesthesia)?
- Does the provider hold the appropriate state sedation permit for the intended level?
- What is the patient's ASA Physical Status classification?
- Has the patient had a pre-sedation medical evaluation within the past 30 days?
- What is the patient's Mallampati airway classification (I–IV)?
- Does the patient have a history of obstructive sleep apnea, COPD, obesity (BMI > 35), or prior difficult intubation?
- Has the patient fasted per ASA guidelines (2 hours clear liquids, 6 hours light meal, 8 hours full meal)?
- Is a responsible adult available to escort the patient and remain for the recovery period?
Documents to Request
- Complete medical history with cardiopulmonary focus
- Current medication list (including sedatives, opioids, benzodiazepines, herbal supplements)
- Airway assessment documentation (Mallampati, thyromental distance, neck mobility, mouth opening)
- Written informed consent for sedation (separate from procedure consent)
- NPO (fasting) status confirmation
- State sedation permit documentation
- Emergency equipment checklist (verified day-of)
- Staff sedation training certifications (ACLS/PALS as required by state)
Step 1: ASA Sedation Continuum and Provider Requirements
Sedation Levels
| Level |
Responsiveness |
Airway |
Spontaneous Ventilation |
Cardiovascular |
ADA Permit Level |
| Minimal sedation (anxiolysis) |
Normal response to verbal stimulation |
Unaffected |
Unaffected |
Unaffected |
May not require separate permit (state-dependent) |
| Moderate sedation |
Purposeful response to verbal or light tactile stimulation |
No intervention required |
Adequate |
Usually maintained |
Moderate sedation permit required |
| Deep sedation |
Purposeful response only to repeated or painful stimulation |
Intervention may be required |
May be inadequate |
Usually maintained |
Deep sedation/GA permit required |
| General anesthesia |
Unarousable even with painful stimulus |
Intervention often required |
Frequently inadequate |
May be impaired |
GA permit required; anesthesiologist or CRNA in most states |
Staffing Requirements (ADA Guidelines)
- Minimal sedation: Operator + trained assistant
- Moderate sedation: Operator + dedicated monitor (separate person whose sole role during sedation is monitoring)
- Deep sedation/GA: Operator + dedicated anesthesia provider + surgical assistant; minimum 3 personnel
Step 2: Pre-Sedation Assessment
Airway Evaluation
| Assessment |
Technique |
Risk Indicator |
| Mallampati classification |
Patient seated, mouth open, tongue protruded without phonation |
Class III–IV: increased difficult airway risk |
| Thyromental distance |
Mentum to thyroid notch |
< 6 cm: potential difficult intubation |
| Mouth opening |
Interincisal distance |
< 3 cm: limited airway access |
| Neck mobility |
Extension range |
Limited extension: may complicate airway management |
| BMI |
Weight/height² |
> 35: increased desaturation risk, difficult mask ventilation |
| Neck circumference |
Circumference at thyroid cartilage |
> 17 inches (male) / > 16 inches (female): OSA risk factor |
Patient Selection Exclusion Criteria for Office-Based Sedation
- ASA IV or above — refer to hospital/surgical center
- Severe untreated OSA without CPAP compliance
- History of malignant hyperthermia (for triggering agents)
- Active upper respiratory infection (postpone 2 weeks)
- Pregnancy (unless emergent and anesthesiology consulted)
- Patient unable to maintain NPO status as directed
- No responsible escort available for post-sedation transport
Step 3: Intraoperative Monitoring and Drug Protocols
Required Monitoring Parameters
| Parameter |
Device |
Recording Frequency |
Action Threshold |
| Pulse oximetry (SpO₂) |
Continuous pulse oximeter |
Continuous; record q5 min |
SpO₂ < 95%: stimulate, reposition airway; < 90%: supplemental O₂, assist ventilation |
| Heart rate |
Pulse oximeter or ECG |
Continuous; record q5 min |
< 50 or > 120: assess and intervene |
| Blood pressure |
Automated NIBP cuff |
q5 min during sedation |
SBP < 90 or > 180: assess and intervene |
| Respiratory rate |
Visual observation or capnography |
Continuous observation; record q5 min |
< 8: stimulate, consider reversal; apnea > 15 sec: assist ventilation |
| End-tidal CO₂ (ETCO₂) |
Capnography (nasal cannula with CO₂ sampling) |
Continuous (required for moderate+ in many states) |
> 50 mmHg or absent waveform: assess ventilation |
| Level of consciousness |
Verbal/tactile stimulation |
q5 min during sedation |
Failure to respond purposefully to verbal: sedation has deepened beyond moderate |
| Temperature |
Thermometer (if GA or prolonged sedation) |
Pre and post procedure |
> 38.5°C unexplained: consider MH in susceptible patients |
Common Sedation Drug Protocols
| Route |
Drugs |
Typical Adult Dose |
Onset |
Notes |
| Oral (minimal) |
Triazolam |
0.25–0.5 mg SL |
15–30 min |
Titrate; elderly start at 0.125 mg |
| Oral (minimal) |
Diazepam |
5–10 mg PO |
30–60 min |
Long half-life; delayed recovery |
| Inhalation (minimal) |
Nitrous oxide/oxygen |
30–50% N₂O titrated |
3–5 min |
Self-limiting; rapid recovery |
| IV (moderate) |
Midazolam |
1–2 mg initial, titrate 0.5 mg q2 min |
1–3 min |
Max ~5 mg in healthy adult; reduce in elderly |
| IV (moderate) |
Fentanyl |
25–50 mcg initial, titrate 25 mcg q5 min |
2–3 min |
Respiratory depression risk; have naloxone ready |
| IV (deep/GA) |
Propofol |
Induction 1–2 mg/kg; infusion 25–75 mcg/kg/min |
30–60 sec |
Requires deep sedation or GA permit; dedicated anesthesia provider |
Reversal Agents
| Agent |
Reverses |
Dose |
Route |
Onset |
Duration |
| Flumazenil |
Benzodiazepines |
0.2 mg initial, repeat 0.2 mg q1 min (max 1 mg) |
IV |
1–2 min |
45–90 min (re-sedation possible) |
| Naloxone |
Opioids |
0.4 mg initial, repeat q2–3 min |
IV/IM |
1–2 min IV, 5 min IM |
30–90 min (re-sedation possible; patient must be monitored) |
Step 4: Recovery and Discharge Criteria
Modified Aldrete Scoring System for Dental Sedation Discharge
| Criterion |
Score 2 |
Score 1 |
Score 0 |
| Activity |
Moves all extremities voluntarily |
Moves 2 extremities |
Unable to move |
| Respiration |
Deep breath, coughs freely |
Dyspnea or limited breathing |
Apneic |
| Circulation |
BP ± 20% of pre-sedation |
BP ± 20–49% of pre-sedation |
BP ± 50% of pre-sedation |
| Consciousness |
Fully awake |
Arousable on calling |
Not responding |
| Oxygen saturation |
SpO₂ > 95% on room air |
Needs supplemental O₂ for SpO₂ > 90% |
SpO₂ < 90% with supplemental O₂ |
Minimum discharge score: 9 out of 10 (no zeros in any category).
Discharge Requirements
- Aldrete score ≥ 9 with no score of 0 in any category
- Vital signs stable and within 20% of baseline for 30 minutes
- Patient can ambulate without assistance (or return to baseline mobility)
- Protective reflexes intact (gag, swallow, cough)
- Nausea/vomiting controlled
- Pain adequately managed
- Responsible adult present to escort patient home
- Written post-sedation instructions provided to patient AND escort
- Emergency contact number provided for after-hours concerns
Step 5: Pediatric Sedation — Special Considerations
AAPD/AAP Pediatric Sedation Guidelines Key Points
| Requirement |
Specification |
| Pre-sedation assessment |
Age-appropriate airway evaluation; weight-based drug dose calculation documented |
| NPO requirements |
Same as adult ASA guidelines; verify with caregiver |
| Monitoring personnel |
Dedicated observer in addition to operator for moderate sedation |
| Weight-based dosing |
All drugs calculated by mg/kg; maximum dose documented BEFORE administration |
| Discharge criteria |
Age-appropriate responsiveness; return to pre-sedation level of consciousness; adequate hydration |
| Documentation |
Include weight, calculated dose, administered dose, monitoring parameters, Aldrete or equivalent score |
Pediatric-Specific Drug Considerations
| Drug |
Pediatric Dose |
Maximum |
Risk |
| Oral midazolam |
0.5 mg/kg (max 20 mg) |
20 mg |
Paradoxical reaction (agitation instead of sedation) in ~2% of children |
| Oral hydroxyzine |
2 mg/kg |
50 mg for < 6 years; 100 mg for ≥ 6 years |
Excessive sedation when combined with other agents |
| Intranasal midazolam |
0.2–0.3 mg/kg |
10 mg |
Burning sensation on administration |
| Nitrous oxide |
30–50% titrated |
50% N₂O |
Nausea risk increases above 50% |
| Oral chloral hydrate |
50–75 mg/kg |
1 gram for infants; 2 grams for children |
Narrow therapeutic window; respiratory depression; prolonged recovery — increasingly avoided |
Pediatric Sedation Red Flags
- Any child under 6 months: extremely high risk; hospital setting mandatory
- Weight ≤ 15 kg: drug volume errors are amplified; double-check all calculations
- Tonsillar hypertrophy (Mallampati III–IV): increased airway obstruction risk under sedation
- Current URI symptoms: postpone sedation 2 weeks minimum
- History of prematurity or reactive airway disease: higher desaturation risk
Checkpoint B: Post-Sedation Alignment (Mandatory)
- Were monitoring parameters recorded at required intervals throughout the procedure?
- Did the patient remain at the intended sedation level, or was a deeper level reached?
- Was the modified Aldrete score ≥ 9 at discharge?
- Was the responsible escort confirmed present before discharge?
- Were post-sedation instructions (no driving, no operating machinery, no major decisions for 24 hours) provided in writing?
Quality Audit
| # |
Criterion |
Pass / Fail |
| 1 |
State sedation permit current and displayed |
|
| 2 |
Pre-sedation medical evaluation documented within 30 days |
|
| 3 |
ASA classification and Mallampati score recorded |
|
| 4 |
NPO status confirmed and documented before sedation |
|
| 5 |
Informed consent for sedation obtained separately from procedure consent |
|
| 6 |
Monitoring devices calibrated and functioning before start |
|
| 7 |
Vital signs recorded at minimum q5 min intervals |
|
| 8 |
Capnography used for moderate sedation and above (per state requirement) |
|
| 9 |
Emergency equipment and reversal agents immediately available |
|
| 10 |
Dedicated monitor present for moderate sedation; dedicated anesthesia provider for deep/GA |
|
| 11 |
Drug doses, routes, and times documented in sedation record |
|
| 12 |
Modified Aldrete score ≥ 9 documented at discharge |
|
| 13 |
Responsible escort confirmed before patient release |
|
| 14 |
Post-sedation instructions provided in writing |
|
| 15 |
Staff ACLS/PALS certifications current per state requirement |
|
Guidelines
- Always plan for rescue from one level deeper than intended — if providing moderate sedation, be equipped and trained to rescue from deep sedation
- The dedicated monitor must not have any other clinical duties during the sedation procedure
- Titrate to effect — administer in small increments and wait for full onset before additional dosing
- Capnography is the earliest indicator of respiratory depression; do not rely solely on pulse oximetry, which is a lagging indicator
- Never discharge a sedated patient without a confirmed responsible adult escort, regardless of how alert the patient appears
- Document the time, dose, and route of every drug administered during the sedation record
- Reversal agents have shorter durations than the drugs they reverse — a patient reversed with flumazenil or naloxone requires extended observation for re-sedation
- Conduct quarterly emergency simulation drills involving the entire sedation team; review and debrief after each drill
1---2name: managing-dental-sedation3description: Documents conscious sedation with patient selection, monitoring parameters, and recovery assessment. Use when providing dental sedation, documenting sedation monitoring, or managing sedation recovery.4---5
6# Managing Dental Sedation
7
8Documents the ASA sedation continuum for dental patients, including patient selection, pre-sedation assessment, intraoperative monitoring, drug protocols, and discharge criteria for minimal, moderate, and deep sedation.
9
10## Why This Skill Exists
11
12Sedation-related adverse events are the leading cause of dental office mortality. Between 2000 and 2020, over 100 documented deaths in US dental offices were attributable to sedation complications — most involving airway compromise in inadequately monitored patients. The ASA sedation continuum means that every patient receiving sedation can unpredictably progress to a deeper level, and the provider must be trained and equipped to rescue from one level deeper than intended.
13
14State dental boards regulate sedation permits with specific staffing, equipment, training, and documentation requirements that vary by sedation level. This skill structures the entire sedation workflow from patient selection through discharge, ensuring compliance with ADA Guidelines for the Use of Sedation and General Anesthesia by Dentists (2016, revised) and state-specific regulations.
15
16---
17
18## Checkpoint A: Pre-Sedation Intake (Mandatory)
19
201. What sedation level is planned (minimal/anxiolysis, moderate, deep, general anesthesia)?
212. Does the provider hold the appropriate state sedation permit for the intended level?
223. What is the patient's ASA Physical Status classification?
234. Has the patient had a pre-sedation medical evaluation within the past 30 days?
245. What is the patient's Mallampati airway classification (I–IV)?
256. Does the patient have a history of obstructive sleep apnea, COPD, obesity (BMI > 35), or prior difficult intubation?
267. Has the patient fasted per ASA guidelines (2 hours clear liquids, 6 hours light meal, 8 hours full meal)?
278. Is a responsible adult available to escort the patient and remain for the recovery period?
28
29### Documents to Request
30
31- Complete medical history with cardiopulmonary focus
32- Current medication list (including sedatives, opioids, benzodiazepines, herbal supplements)
33- Airway assessment documentation (Mallampati, thyromental distance, neck mobility, mouth opening)
34- Written informed consent for sedation (separate from procedure consent)
35- NPO (fasting) status confirmation
36- State sedation permit documentation
37- Emergency equipment checklist (verified day-of)
38- Staff sedation training certifications (ACLS/PALS as required by state)
39
40---
41
42## Step 1: ASA Sedation Continuum and Provider Requirements
43
44### Sedation Levels
45
46| Level | Responsiveness | Airway | Spontaneous Ventilation | Cardiovascular | ADA Permit Level |
47|-------|---------------|--------|------------------------|---------------|-----------------|
48| Minimal sedation (anxiolysis) | Normal response to verbal stimulation | Unaffected | Unaffected | Unaffected | May not require separate permit (state-dependent) |
49| Moderate sedation | Purposeful response to verbal or light tactile stimulation | No intervention required | Adequate | Usually maintained | Moderate sedation permit required |
50| Deep sedation | Purposeful response only to repeated or painful stimulation | Intervention may be required | May be inadequate | Usually maintained | Deep sedation/GA permit required |
51| General anesthesia | Unarousable even with painful stimulus | Intervention often required | Frequently inadequate | May be impaired | GA permit required; anesthesiologist or CRNA in most states |
52
53### Staffing Requirements (ADA Guidelines)
54
55- **Minimal sedation**: Operator + trained assistant
56- **Moderate sedation**: Operator + dedicated monitor (separate person whose sole role during sedation is monitoring)
57- **Deep sedation/GA**: Operator + dedicated anesthesia provider + surgical assistant; minimum 3 personnel
58
59---
60
61## Step 2: Pre-Sedation Assessment
62
63### Airway Evaluation
64
65| Assessment | Technique | Risk Indicator |
66|-----------|-----------|---------------|
67| Mallampati classification | Patient seated, mouth open, tongue protruded without phonation | Class III–IV: increased difficult airway risk |
68| Thyromental distance | Mentum to thyroid notch | < 6 cm: potential difficult intubation |
69| Mouth opening | Interincisal distance | < 3 cm: limited airway access |
70| Neck mobility | Extension range | Limited extension: may complicate airway management |
71| BMI | Weight/height² | > 35: increased desaturation risk, difficult mask ventilation |
72| Neck circumference | Circumference at thyroid cartilage | > 17 inches (male) / > 16 inches (female): OSA risk factor |
73
74### Patient Selection Exclusion Criteria for Office-Based Sedation
75
76- ASA IV or above — refer to hospital/surgical center
77- Severe untreated OSA without CPAP compliance
78- History of malignant hyperthermia (for triggering agents)
79- Active upper respiratory infection (postpone 2 weeks)
80- Pregnancy (unless emergent and anesthesiology consulted)
81- Patient unable to maintain NPO status as directed
82- No responsible escort available for post-sedation transport
83
84---
85
86## Step 3: Intraoperative Monitoring and Drug Protocols
87
88### Required Monitoring Parameters
89
90| Parameter | Device | Recording Frequency | Action Threshold |
91|-----------|--------|-------------------|-----------------|
92| Pulse oximetry (SpO₂) | Continuous pulse oximeter | Continuous; record q5 min | SpO₂ < 95%: stimulate, reposition airway; < 90%: supplemental O₂, assist ventilation |
93| Heart rate | Pulse oximeter or ECG | Continuous; record q5 min | < 50 or > 120: assess and intervene |
94| Blood pressure | Automated NIBP cuff | q5 min during sedation | SBP < 90 or > 180: assess and intervene |
95| Respiratory rate | Visual observation or capnography | Continuous observation; record q5 min | < 8: stimulate, consider reversal; apnea > 15 sec: assist ventilation |
96| End-tidal CO₂ (ETCO₂) | Capnography (nasal cannula with CO₂ sampling) | Continuous (required for moderate+ in many states) | > 50 mmHg or absent waveform: assess ventilation |
97| Level of consciousness | Verbal/tactile stimulation | q5 min during sedation | Failure to respond purposefully to verbal: sedation has deepened beyond moderate |
98| Temperature | Thermometer (if GA or prolonged sedation) | Pre and post procedure | > 38.5°C unexplained: consider MH in susceptible patients |
99
100### Common Sedation Drug Protocols
101
102| Route | Drugs | Typical Adult Dose | Onset | Notes |
103|-------|-------|-------------------|-------|-------|
104| Oral (minimal) | Triazolam | 0.25–0.5 mg SL | 15–30 min | Titrate; elderly start at 0.125 mg |
105| Oral (minimal) | Diazepam | 5–10 mg PO | 30–60 min | Long half-life; delayed recovery |
106| Inhalation (minimal) | Nitrous oxide/oxygen | 30–50% N₂O titrated | 3–5 min | Self-limiting; rapid recovery |
107| IV (moderate) | Midazolam | 1–2 mg initial, titrate 0.5 mg q2 min | 1–3 min | Max ~5 mg in healthy adult; reduce in elderly |
108| IV (moderate) | Fentanyl | 25–50 mcg initial, titrate 25 mcg q5 min | 2–3 min | Respiratory depression risk; have naloxone ready |
109| IV (deep/GA) | Propofol | Induction 1–2 mg/kg; infusion 25–75 mcg/kg/min | 30–60 sec | Requires deep sedation or GA permit; dedicated anesthesia provider |
110
111### Reversal Agents
112
113| Agent | Reverses | Dose | Route | Onset | Duration |
114|-------|---------|------|-------|-------|---------|
115| Flumazenil | Benzodiazepines | 0.2 mg initial, repeat 0.2 mg q1 min (max 1 mg) | IV | 1–2 min | 45–90 min (re-sedation possible) |
116| Naloxone | Opioids | 0.4 mg initial, repeat q2–3 min | IV/IM | 1–2 min IV, 5 min IM | 30–90 min (re-sedation possible; patient must be monitored) |
117
118---
119
120## Step 4: Recovery and Discharge Criteria
121
122### Modified Aldrete Scoring System for Dental Sedation Discharge
123
124| Criterion | Score 2 | Score 1 | Score 0 |
125|----------|---------|---------|---------|
126| Activity | Moves all extremities voluntarily | Moves 2 extremities | Unable to move |
127| Respiration | Deep breath, coughs freely | Dyspnea or limited breathing | Apneic |
128| Circulation | BP ± 20% of pre-sedation | BP ± 20–49% of pre-sedation | BP ± 50% of pre-sedation |
129| Consciousness | Fully awake | Arousable on calling | Not responding |
130| Oxygen saturation | SpO₂ > 95% on room air | Needs supplemental O₂ for SpO₂ > 90% | SpO₂ < 90% with supplemental O₂ |
131
132**Minimum discharge score: 9 out of 10 (no zeros in any category).**
133
134### Discharge Requirements
135
1361. Aldrete score ≥ 9 with no score of 0 in any category
1372. Vital signs stable and within 20% of baseline for 30 minutes
1383. Patient can ambulate without assistance (or return to baseline mobility)
1394. Protective reflexes intact (gag, swallow, cough)
1405. Nausea/vomiting controlled
1416. Pain adequately managed
1427. Responsible adult present to escort patient home
1438. Written post-sedation instructions provided to patient AND escort
1449. Emergency contact number provided for after-hours concerns
145
146---
147
148## Step 5: Pediatric Sedation — Special Considerations
149
150### AAPD/AAP Pediatric Sedation Guidelines Key Points
151
152| Requirement | Specification |
153|-------------|--------------|
154| Pre-sedation assessment | Age-appropriate airway evaluation; weight-based drug dose calculation documented |
155| NPO requirements | Same as adult ASA guidelines; verify with caregiver |
156| Monitoring personnel | Dedicated observer in addition to operator for moderate sedation |
157| Weight-based dosing | All drugs calculated by mg/kg; maximum dose documented BEFORE administration |
158| Discharge criteria | Age-appropriate responsiveness; return to pre-sedation level of consciousness; adequate hydration |
159| Documentation | Include weight, calculated dose, administered dose, monitoring parameters, Aldrete or equivalent score |
160
161### Pediatric-Specific Drug Considerations
162
163| Drug | Pediatric Dose | Maximum | Risk |
164|------|---------------|---------|------|
165| Oral midazolam | 0.5 mg/kg (max 20 mg) | 20 mg | Paradoxical reaction (agitation instead of sedation) in ~2% of children |
166| Oral hydroxyzine | 2 mg/kg | 50 mg for < 6 years; 100 mg for ≥ 6 years | Excessive sedation when combined with other agents |
167| Intranasal midazolam | 0.2–0.3 mg/kg | 10 mg | Burning sensation on administration |
168| Nitrous oxide | 30–50% titrated | 50% N₂O | Nausea risk increases above 50% |
169| Oral chloral hydrate | 50–75 mg/kg | 1 gram for infants; 2 grams for children | Narrow therapeutic window; respiratory depression; prolonged recovery — increasingly avoided |
170
171### Pediatric Sedation Red Flags
172
173- Any child under 6 months: extremely high risk; hospital setting mandatory
174- Weight ≤ 15 kg: drug volume errors are amplified; double-check all calculations
175- Tonsillar hypertrophy (Mallampati III–IV): increased airway obstruction risk under sedation
176- Current URI symptoms: postpone sedation 2 weeks minimum
177- History of prematurity or reactive airway disease: higher desaturation risk
178
179---
180
181## Checkpoint B: Post-Sedation Alignment (Mandatory)
182
1831. Were monitoring parameters recorded at required intervals throughout the procedure?
1842. Did the patient remain at the intended sedation level, or was a deeper level reached?
1853. Was the modified Aldrete score ≥ 9 at discharge?
1864. Was the responsible escort confirmed present before discharge?
1875. Were post-sedation instructions (no driving, no operating machinery, no major decisions for 24 hours) provided in writing?
188
189---
190
191## Quality Audit
192
193| # | Criterion | Pass / Fail |
194|---|-----------|-------------|
195| 1 | State sedation permit current and displayed | |
196| 2 | Pre-sedation medical evaluation documented within 30 days | |
197| 3 | ASA classification and Mallampati score recorded | |
198| 4 | NPO status confirmed and documented before sedation | |
199| 5 | Informed consent for sedation obtained separately from procedure consent | |
200| 6 | Monitoring devices calibrated and functioning before start | |
201| 7 | Vital signs recorded at minimum q5 min intervals | |
202| 8 | Capnography used for moderate sedation and above (per state requirement) | |
203| 9 | Emergency equipment and reversal agents immediately available | |
204| 10 | Dedicated monitor present for moderate sedation; dedicated anesthesia provider for deep/GA | |
205| 11 | Drug doses, routes, and times documented in sedation record | |
206| 12 | Modified Aldrete score ≥ 9 documented at discharge | |
207| 13 | Responsible escort confirmed before patient release | |
208| 14 | Post-sedation instructions provided in writing | |
209| 15 | Staff ACLS/PALS certifications current per state requirement | |
210
211---
212
213## Guidelines
214
215- Always plan for rescue from one level deeper than intended — if providing moderate sedation, be equipped and trained to rescue from deep sedation
216- The dedicated monitor must not have any other clinical duties during the sedation procedure
217- Titrate to effect — administer in small increments and wait for full onset before additional dosing
218- Capnography is the earliest indicator of respiratory depression; do not rely solely on pulse oximetry, which is a lagging indicator
219- Never discharge a sedated patient without a confirmed responsible adult escort, regardless of how alert the patient appears
220- Document the time, dose, and route of every drug administered during the sedation record
221- Reversal agents have shorter durations than the drugs they reverse — a patient reversed with flumazenil or naloxone requires extended observation for re-sedation
222- Conduct quarterly emergency simulation drills involving the entire sedation team; review and debrief after each drill
CaseMark